Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of pertuzumab + trastuzumab with or without chemotherapy, followed by T-DM1, in HER2-positive metastatic breast cancer
2012-002556-17Phase 2Completed
- Sponsor
- Unicancer
- Start
- Apr 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of pertuzumab, trastuzumab, trastuzumab emtansine, paclitaxel and vinorelbine in HER2-enriched breast cancer (HER2+) (2 arms), sponsored by Unicancer. Primary endpoint: Overall survival at 24 months (primary analysis). Started Apr 2013; status: completed.
02
Drugs
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2012-002556-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002556-17.